Simpson, Curran Matthew,Yoo, Stephen,Kozarsky, Karen Fran,Reinhardt, Rickey Robert,Coruzzi, Laura A.
申请号：
AU2017250797
公开号：
AU2017250797A1
申请日:
2017.04.14
申请国别(地区):
AU
年份:
2018
代理人:
摘要：
Compositions and methods are described for the delivery of a fully human post- translationally modified (HuPTM) monoclonal antibody ("mAb") or the antigen-binding fragment of a mAb against human vascular endothelial growth factor ("hVEGF") - such as, e.g., a fully human-glycosylated (HuGly) anti-hVEGF antigen-binding fragment - to the retina/vitreal humour in the eye(s) of human subjects diagnosed with ocular diseases caused by increased neovascularization, for example, neovascular age-related macular degeneration ("nAMD"), also known as "wet" age-related macular degeneration ("WAMD"), age-related macular degeneration ("AMD"), and diabetic retinopathy.
